Ruxoprubart

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameRuxoprubart
Drug Alias NameAnti-BbNM-8074NM8074
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement factor B inhibitors
TargetsComplement factor B
Therapy Area/IndicationsC3 glomerulopathyHemoglobinuria, ParoxysmalAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovelMed Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovelMed Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsC3 glomerulopathyHemoglobinuria, ParoxysmalAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A